Should you buy BioMarin Pharmaceutical stock now?
Yes, the technical signal for BioMarin Pharmaceutical is currently BUY. BioMarin Pharmaceutical trades at $59.42 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.755 with falling momentum (signal: 0.859); RSI is at 53.5 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $87.92 points to 48.0% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for BioMarin Pharmaceutical stock?
The average analyst price target for BioMarin Pharmaceutical is $87.92. The current price is $59.42, which gives an upside of 48.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $79.13 and $96.71.
Is BioMarin Pharmaceutical a dividend stock?
No, BioMarin Pharmaceutical does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of BioMarin Pharmaceutical stock?
BioMarin Pharmaceutical is rated as a stock with moderately low risk. the annual standard deviation is 34.1%, which classifies the stock as moderately low risk.
Is BioMarin Pharmaceutical overvalued?
No, BioMarin Pharmaceutical is considered undervalued based on the analyst price target (48.0% upside). BioMarin Pharmaceutical has the following valuation ratios: a P/E ratio of 43.7 (highly valued), a P/S ratio of 3.6, a P/B ratio of 1.9. The analyst price target suggests that the stock is undervalued by 48.0%.
Is BioMarin Pharmaceutical overbought?
No, BioMarin Pharmaceutical is not overbought. RSI is at 53.5 (neutral zone). The technical indicators show: RSI is at 53.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.6% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next BioMarin Pharmaceutical earnings report?
BioMarin Pharmaceutical reports earnings TODAY, August 6, 2026! The stock currently trades at $59.42. Watch how the price reacts after the release. With a P/E ratio of 43.7, the market will be watching closely whether earnings meet expectations.
Is BioMarin Pharmaceutical shorted?
Yes, BioMarin Pharmaceutical is shorted with 7.4% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying BioMarin Pharmaceutical stock?
No, insiders are not buying BioMarin Pharmaceutical shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 116,364 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 7,946,674 $ sold. Active sellers include Hubbard Cristin, Friberg Gregory R, Davis George Eric and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is BioMarin Pharmaceutical a good stock?
Based on our total score, BioMarin Pharmaceutical is rated as a mediocre stock with a total score of 56 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 42/100, Quality: 54/100, Momentum: 71/100. In addition: analysts see 48.0% upside to the price target; technical signal: Strong Buy. Whether BioMarin Pharmaceutical is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for BioMarin Pharmaceutical stock?
The outlook for BioMarin Pharmaceutical based on current data: the average analyst price target is $87.92 (+48.0%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price; the P/E ratio is 43.7 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is BioMarin Pharmaceutical stock moving?
BioMarin Pharmaceutical is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 7.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can BioMarin Pharmaceutical go?
The average analyst price target for BioMarin Pharmaceutical is $87.92, which corresponds to a potential gain of 48.0% from the current price of $59.42. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can BioMarin Pharmaceutical fall?
We lack enough history to give a specific floor for BioMarin Pharmaceutical. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does BioMarin Pharmaceutical do?
BioMarin Pharmaceutical Inc. (bmrn.us) udvikler og sælger behandlinger til folk med alvorlige, sjældne sygdomme. De tjener penge på flere godkendte lægemidler, som hjælper patienter med stofskiftesygdomme.
Blandt deres vigtigste produkter er Vimizim og Naglazyme, som bruges m... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate BioMarin Pharmaceutical as an investment.
Did BioMarin Pharmaceutical raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from BioMarin Pharmaceutical. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is BioMarin Pharmaceutical making money or losing money?
Yes, BioMarin Pharmaceutical is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.3% — which is moderate. The operating margin (profit before interest and taxes) is 18.0%. At a P/E ratio of 43.7, you currently pay 43.7 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can BioMarin Pharmaceutical go bankrupt?
The bankruptcy risk of BioMarin Pharmaceutical is rated as low. Altman Z2 (a model for assessing financial distress) is 6.07 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 24% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does BioMarin Pharmaceutical have a lot of debt?
No, BioMarin Pharmaceutical has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 24%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can BioMarin Pharmaceutical service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 10.4x, and the company has more cash than debt (net cash).
